MA27710A1 - Formulations pharmaceutiques liquides de palonosetrone - Google Patents
Formulations pharmaceutiques liquides de palonosetroneInfo
- Publication number
- MA27710A1 MA27710A1 MA28440A MA28440A MA27710A1 MA 27710 A1 MA27710 A1 MA 27710A1 MA 28440 A MA28440 A MA 28440A MA 28440 A MA28440 A MA 28440A MA 27710 A1 MA27710 A1 MA 27710A1
- Authority
- MA
- Morocco
- Prior art keywords
- palonosetrone
- pharmaceutical formulations
- liquid pharmaceutical
- palonosetronone
- formulations
- Prior art date
Links
- 239000007788 liquid Substances 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 230000008673 vomiting Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4747—Quinolines; Isoquinolines spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
- B65B3/04—Methods of, or means for, filling the material into the containers or receptacles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B55/00—Preserving, protecting or purifying packages or package contents in association with packaging
- B65B55/02—Sterilising, e.g. of complete packages
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mechanical Engineering (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
L'invention concerne des formulations liquides de palonosétrone stables au stockage en vue de réduire, par la palonosétrone, les vomissements provoqués par la chimiothérapie et la radiothérapie. Les formulations sont utilisées notamment pour la préparation de médicaments liquides pouvant être administrés par voie orale et intraveineuse.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44435103P | 2003-01-30 | 2003-01-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA27710A1 true MA27710A1 (fr) | 2006-01-02 |
Family
ID=32825409
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA28440A MA27710A1 (fr) | 2003-01-30 | 2005-08-12 | Formulations pharmaceutiques liquides de palonosetrone |
Country Status (41)
Country | Link |
---|---|
US (9) | US7947724B2 (fr) |
EP (2) | EP2008659A1 (fr) |
JP (2) | JP5461763B2 (fr) |
KR (1) | KR101113084B1 (fr) |
CN (2) | CN102813621A (fr) |
AP (1) | AP2110A (fr) |
AR (1) | AR042977A1 (fr) |
AT (1) | ATE410167T1 (fr) |
AU (1) | AU2004208505C1 (fr) |
BR (1) | BRPI0407121B8 (fr) |
CA (5) | CA2573363A1 (fr) |
CR (1) | CR7921A (fr) |
CY (1) | CY1108660T1 (fr) |
DE (1) | DE602004016967D1 (fr) |
DK (1) | DK1601359T3 (fr) |
EA (1) | EA014066B1 (fr) |
EC (1) | ECSP055938A (fr) |
ES (1) | ES2315635T3 (fr) |
GE (1) | GEP20084445B (fr) |
HK (1) | HK1076401A1 (fr) |
HR (1) | HRP20050676B1 (fr) |
IL (1) | IL169859A (fr) |
IS (1) | IS7984A (fr) |
JO (1) | JO2735B1 (fr) |
MA (1) | MA27710A1 (fr) |
MX (1) | MXPA05008028A (fr) |
MY (1) | MY144036A (fr) |
NO (1) | NO329500B1 (fr) |
NZ (1) | NZ541533A (fr) |
PA (1) | PA8594801A1 (fr) |
PE (1) | PE20050066A1 (fr) |
PL (1) | PL378398A1 (fr) |
PT (1) | PT1601359E (fr) |
RS (1) | RS20050578A (fr) |
SI (1) | SI1601359T1 (fr) |
TN (1) | TNSN05180A1 (fr) |
TW (1) | TWI342212B (fr) |
UA (1) | UA90449C2 (fr) |
UY (1) | UY28175A1 (fr) |
WO (1) | WO2004067005A1 (fr) |
ZA (1) | ZA200506917B (fr) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003302072A1 (en) * | 2002-11-15 | 2004-06-15 | Helsinn Healthcare Sa | Palonosetron for the treatment of chemotherapy-induced emesis |
JO2735B1 (en) | 2003-01-30 | 2013-09-15 | هيلسين هيلث كير أس ايه. | Liquid pharmaceutical formations of balloonosterone |
US8598219B2 (en) | 2003-01-30 | 2013-12-03 | Helsinn Healthcare Sa | Liquid pharmaceutical formulations of palonosetron |
MY143789A (en) * | 2003-02-18 | 2011-07-15 | Helsinn Healthcare Sa | Use of palonosetron treating post- operative nausea and vomiting |
CN100336508C (zh) * | 2005-02-23 | 2007-09-12 | 重庆医药工业研究院有限责任公司 | 一种稳定的帕洛诺司琼注射液 |
CN100455286C (zh) * | 2006-11-21 | 2009-01-28 | 深圳海创医药科技发展有限公司 | 帕洛诺司琼注射液及其制备方法 |
US9061076B2 (en) | 2007-05-25 | 2015-06-23 | North Carolina State University | Viral nanoparticle cell-targeted delivery platform |
US20100048607A1 (en) * | 2008-08-25 | 2010-02-25 | Chandrashekhar Kocherlakota | Formulations comprising palonosetron |
WO2010077669A2 (fr) | 2008-12-08 | 2010-07-08 | Teva Pharmaceutical Industries Ltd. | Formulation de palonosétron |
US20130213393A1 (en) | 2009-12-22 | 2013-08-22 | Evoke Pharma, Inc. | Nasal formulations of metoclopramide |
EP2499137A1 (fr) | 2009-11-13 | 2012-09-19 | Helsinn Healthcare S.A. | Metabolites de palonosetron |
ES2623503T3 (es) | 2009-11-18 | 2017-07-11 | Helsinn Healthcare Sa | Composiciones para tratar náuseas y vómitos mediados centralmente |
EP2722045B1 (fr) | 2009-11-18 | 2016-07-06 | Helsinn Healthcare SA | Compositions pour traiter les nausées et vomissements à médiation centrale |
KR101368587B1 (ko) * | 2010-12-27 | 2014-03-05 | 주식회사 삼양바이오팜 | 오심 또는 구토 방지용 조성물 |
EP2759298B1 (fr) | 2011-10-18 | 2018-01-17 | Helsinn Healthcare SA | Combinaisons thérapeutiques comprenant netupitant et palonosetron |
CN105934247A (zh) | 2013-12-23 | 2016-09-07 | 株式会社三养生物制药 | 包含帕洛诺司琼的药物组合物 |
CN104784107A (zh) * | 2014-01-17 | 2015-07-22 | 南京瑞尔医药有限公司 | 一种盐酸托烷司琼口服液的制备方法 |
KR20160128573A (ko) * | 2015-04-29 | 2016-11-08 | 주식회사 삼양바이오팜 | 약제학적 패키지 |
LT3435980T (lt) * | 2016-06-06 | 2020-02-25 | Helsinn Healthcare Sa | Fiziologiškai subalansuotos injekcinės fosnetupitanto kompozicijos |
JP6768404B2 (ja) * | 2016-08-12 | 2020-10-14 | 武田テバファーマ株式会社 | パロノセトロン又はその薬学的に許容される塩を含む医薬組成物 |
JP6705348B2 (ja) * | 2016-09-23 | 2020-06-03 | ニプロ株式会社 | 液体製剤、及び、パロノセトロンの安定性を向上する方法 |
JP6642377B2 (ja) * | 2016-10-25 | 2020-02-05 | ニプロ株式会社 | 液体製剤、及び、パロノセトロンの安定性を向上する方法 |
KR101802183B1 (ko) * | 2016-11-16 | 2017-11-28 | 주식회사 유영제약 | 팔로노세트론을 활성성분으로 함유하는 약제학적 조성물 |
EP3672964A4 (fr) | 2017-08-21 | 2021-05-26 | Leiutis Pharmaceuticals Pvt. Ltd. | Nouvelles formulations à triple combinaison pour une thérapie antiémétique |
HUE062180T2 (hu) * | 2018-01-12 | 2023-09-28 | Orion Corp | Palonosetron szemcsepp a hányinger és a hányás kezelésére vagy megelõzésére |
JP7090845B2 (ja) * | 2018-08-03 | 2022-06-27 | 高田製薬株式会社 | パロノセトロン含有液体組成物 |
JP7438802B2 (ja) * | 2020-03-23 | 2024-02-27 | シオノギファーマ株式会社 | パロノセトロン含有組成物 |
WO2024147073A1 (fr) * | 2023-01-03 | 2024-07-11 | Helsinn Healthcare Sa | Formulations orales liquides de nétupitant et de palonosétron |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS599539B2 (ja) * | 1979-11-13 | 1984-03-03 | 日本化薬株式会社 | ニトログリセリン水溶液及びその製造法 |
US4695578A (en) | 1984-01-25 | 1987-09-22 | Glaxo Group Limited | 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances |
EP0200444B1 (fr) | 1985-04-27 | 1992-11-11 | Beecham Group Plc | Azabicyclononyl-indazole carboxamide ayant une activité antagoniste de la 5-HT |
US4937247A (en) | 1985-04-27 | 1990-06-26 | Beecham Group P.L.C. | 1-acyl indazoles |
GB8516083D0 (en) | 1985-06-25 | 1985-07-31 | Glaxo Group Ltd | Heterocyclic compounds |
US5578628A (en) | 1985-06-25 | 1996-11-26 | Glaxo Group Limited | Medicaments for the treatment of nausea and vomiting |
US5240954A (en) | 1985-06-25 | 1993-08-31 | Glaxo Group Limited | Medicaments |
US4906755A (en) | 1986-11-03 | 1990-03-06 | Merrell Dow Pharmaceuticals Inc. | Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and related compounds |
US5360800A (en) | 1987-09-03 | 1994-11-01 | Glaxo Group Limited | Tetrahydro-1H-pyrido[4,3-b]indol-1-one derivatives |
US5011846A (en) | 1988-02-23 | 1991-04-30 | Merrell Dow Pharmaceuticals Inc. | Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof |
US5344658A (en) | 1989-06-28 | 1994-09-06 | Glaxo Group Limited | Process and composition using ondansetron |
GB8914804D0 (en) | 1989-06-28 | 1989-08-16 | Glaxo Group Ltd | Process |
ZA909529B (en) | 1989-11-28 | 1992-08-26 | Syntex Inc | New tricyclic compounds |
WO1992019617A2 (fr) | 1991-05-03 | 1992-11-12 | G.D. Searle & Co. | Composes de dibenzoxazepine substituee, compositions pharmaceutiques et procedes d'utilisation |
US5272137A (en) | 1992-02-14 | 1993-12-21 | Mcneil-Pfc, Inc. | Aqueous pharmaceutical suspension for pharmaceutical actives |
GB9305593D0 (en) * | 1993-03-18 | 1993-05-05 | Smithkline Beecham Plc | Pharmaceuticals |
US5567818A (en) * | 1994-07-08 | 1996-10-22 | Syntex (U.S.A.) Inc. | Processes for preparing 2-(1-azabicyclo[2.2.2]oct-3-yl)-1H-benz[de] isoquinolin-1-one derivatives and intermediates useful therein |
GB9423588D0 (en) | 1994-11-22 | 1995-01-11 | Glaxo Wellcome Inc | Compositions |
GB9423511D0 (en) | 1994-11-22 | 1995-01-11 | Glaxo Wellcome Inc | Compositions |
US5576317A (en) * | 1994-12-09 | 1996-11-19 | Pfizer Inc. | NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis |
JP3845902B2 (ja) * | 1996-07-09 | 2006-11-15 | ソニー株式会社 | 磁気記録再生装置 |
ATA156496A (de) | 1996-09-03 | 1997-10-15 | Nycomed Austria Gmbh | Pharmazeutische zusammensetzung |
GB9625589D0 (en) * | 1996-12-10 | 1997-01-29 | Boots Co Plc | Therapeutic agents |
US20030095926A1 (en) | 1997-10-01 | 2003-05-22 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract |
GB9721139D0 (en) | 1997-10-07 | 1997-12-03 | Glaxo Group Ltd | Medicaments |
US6294548B1 (en) | 1998-05-04 | 2001-09-25 | Hoffmann-La Roche Inc. | Multidose vial formulations for administering endo-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride |
US6132758A (en) * | 1998-06-01 | 2000-10-17 | Schering Corporation | Stabilized antihistamine syrup |
DE19833119A1 (de) | 1998-07-23 | 2000-01-27 | Roche Diagnostics Gmbh | Spritzfertige Injektionslösungen enthaltend Carvedilol |
CA2340225A1 (fr) * | 1998-10-27 | 2000-05-04 | Wesley Wehsin Han | Systeme conservateur contenant un savon a base d'acides gras/acides amines pour compositions pharmaceutiques a administration locale |
US6699852B2 (en) * | 2000-12-20 | 2004-03-02 | Bristol-Myers Squibb Pharma Company | Substituted pyridoindoles as serotonin agonists and antagonists |
WO2002092082A1 (fr) | 2001-05-11 | 2002-11-21 | Mitsubishi Pharma Corporation | Produit d'injection stable a des concentrations elevees contenant un derive de pyrazolone |
AU2003237657A1 (en) | 2002-05-24 | 2003-12-12 | Epidauros Biotechnologie Ag | Means and methods for improved treatment using "setrones" |
AU2003302072A1 (en) | 2002-11-15 | 2004-06-15 | Helsinn Healthcare Sa | Palonosetron for the treatment of chemotherapy-induced emesis |
EP1581221B1 (fr) * | 2002-12-19 | 2011-05-18 | Bristol-Myers Squibb Company | Gamma-carbolines tricycliques substituees utilisees comme agonistes et antagonistes du recepteur de la serotonine |
DE602004005814T2 (de) | 2003-01-13 | 2008-01-10 | Dynogen Pharmaceuticals Inc., Waltham | Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus |
JO2735B1 (en) * | 2003-01-30 | 2013-09-15 | هيلسين هيلث كير أس ايه. | Liquid pharmaceutical formations of balloonosterone |
US8598219B2 (en) | 2003-01-30 | 2013-12-03 | Helsinn Healthcare Sa | Liquid pharmaceutical formulations of palonosetron |
MY143789A (en) * | 2003-02-18 | 2011-07-15 | Helsinn Healthcare Sa | Use of palonosetron treating post- operative nausea and vomiting |
-
2004
- 2004-01-27 JO JO20042A patent/JO2735B1/en active
- 2004-01-28 TW TW093101810A patent/TWI342212B/zh not_active IP Right Cessation
- 2004-01-29 MY MYPI20040261A patent/MY144036A/en unknown
- 2004-01-29 AR ARP040100279A patent/AR042977A1/es not_active Application Discontinuation
- 2004-01-30 PA PA20048594801A patent/PA8594801A1/es unknown
- 2004-01-30 CA CA002573363A patent/CA2573363A1/fr not_active Abandoned
- 2004-01-30 CA CA002573241A patent/CA2573241A1/fr not_active Abandoned
- 2004-01-30 CN CN2012102874523A patent/CN102813621A/zh active Pending
- 2004-01-30 MX MXPA05008028A patent/MXPA05008028A/es active IP Right Grant
- 2004-01-30 PT PT04706657T patent/PT1601359E/pt unknown
- 2004-01-30 RS YUP-2005/0578A patent/RS20050578A/sr unknown
- 2004-01-30 CN CNA2004800063221A patent/CN1758911A/zh active Pending
- 2004-01-30 CA CA002573194A patent/CA2573194A1/fr not_active Abandoned
- 2004-01-30 PE PE2004000115A patent/PE20050066A1/es not_active Application Discontinuation
- 2004-01-30 PL PL378398A patent/PL378398A1/pl not_active Application Discontinuation
- 2004-01-30 JP JP2006501686A patent/JP5461763B2/ja not_active Expired - Lifetime
- 2004-01-30 UY UY28175A patent/UY28175A1/es not_active IP Right Cessation
- 2004-01-30 DE DE602004016967T patent/DE602004016967D1/de not_active Expired - Lifetime
- 2004-01-30 CA CA002573228A patent/CA2573228A1/fr not_active Abandoned
- 2004-01-30 SI SI200430976T patent/SI1601359T1/sl unknown
- 2004-01-30 EA EA200501203A patent/EA014066B1/ru unknown
- 2004-01-30 NZ NZ541533A patent/NZ541533A/en not_active IP Right Cessation
- 2004-01-30 UA UAA200508414A patent/UA90449C2/ru unknown
- 2004-01-30 EP EP08015410A patent/EP2008659A1/fr not_active Withdrawn
- 2004-01-30 ES ES04706657T patent/ES2315635T3/es not_active Expired - Lifetime
- 2004-01-30 GE GEAP20048958A patent/GEP20084445B/en unknown
- 2004-01-30 AU AU2004208505A patent/AU2004208505C1/en not_active Expired
- 2004-01-30 KR KR1020057014093A patent/KR101113084B1/ko active IP Right Review Request
- 2004-01-30 WO PCT/EP2004/000888 patent/WO2004067005A1/fr active Application Filing
- 2004-01-30 CA CA002514224A patent/CA2514224C/fr not_active Expired - Lifetime
- 2004-01-30 BR BRPI0407121A patent/BRPI0407121B8/pt active IP Right Grant
- 2004-01-30 AT AT04706657T patent/ATE410167T1/de active
- 2004-01-30 AP AP2005003382A patent/AP2110A/xx active
- 2004-01-30 EP EP04706657A patent/EP1601359B1/fr not_active Revoked
- 2004-01-30 DK DK04706657T patent/DK1601359T3/da active
-
2005
- 2005-07-21 US US11/186,311 patent/US7947724B2/en not_active Expired - Lifetime
- 2005-07-22 CR CR7921A patent/CR7921A/es unknown
- 2005-07-25 IL IL169859A patent/IL169859A/en active IP Right Grant
- 2005-07-27 TN TNP2005000180A patent/TNSN05180A1/en unknown
- 2005-07-27 HR HRP20050676AA patent/HRP20050676B1/hr active IP Right Review Request
- 2005-07-29 EC EC2005005938A patent/ECSP055938A/es unknown
- 2005-08-12 MA MA28440A patent/MA27710A1/fr unknown
- 2005-08-15 IS IS7984A patent/IS7984A/is unknown
- 2005-08-26 NO NO20053987A patent/NO329500B1/no not_active IP Right Cessation
- 2005-08-29 ZA ZA200506917A patent/ZA200506917B/xx unknown
- 2005-12-07 HK HK05111168A patent/HK1076401A1/xx not_active IP Right Cessation
-
2006
- 2006-03-24 US US11/388,270 patent/US7960424B2/en not_active Expired - Lifetime
- 2006-03-24 US US11/388,268 patent/US7947725B2/en active Active
-
2008
- 2008-12-22 CY CY20081101485T patent/CY1108660T1/el unknown
-
2011
- 2011-04-14 US US13/087,012 patent/US8518981B2/en not_active Expired - Lifetime
- 2011-07-28 JP JP2011165212A patent/JP5551658B2/ja not_active Expired - Lifetime
-
2013
- 2013-05-23 US US13/901,288 patent/US8598218B2/en not_active Expired - Lifetime
- 2013-10-14 US US14/052,925 patent/US20140039000A1/en not_active Abandoned
- 2013-11-04 US US14/070,981 patent/US9308266B2/en not_active Expired - Fee Related
-
2015
- 2015-09-16 US US14/855,564 patent/US9457020B2/en not_active Expired - Lifetime
-
2016
- 2016-07-14 US US15/209,995 patent/US20160317440A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA27710A1 (fr) | Formulations pharmaceutiques liquides de palonosetrone | |
MA38576A1 (fr) | Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières | |
MA30470B1 (fr) | Compositions pharmaceutiques d'anticorps anti-cd40 antagoniste. | |
DK1317419T3 (da) | Cyanophenoxycarboxylsyre-forbindelser og sammensætninger til at levere aktive midler | |
HK1096034A1 (en) | A solid dosage form comprising a fibrate | |
MA29744B1 (fr) | Formulations posologiques solides de medicaments presentant une adsorption buccale amelioree | |
BG66093B1 (bg) | Състави с контролирано освобождаване, съдържащи нимесулид | |
CA2431606A1 (fr) | Methode et compositions comprenant des formulations qui contiennent des huiles de lecithine et des ains pour proteger le tractus gastro-intestinal et pour fournir une activite therapeutique amelioree | |
ATE396967T1 (de) | (5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten | |
BRPI0518266A2 (pt) | medicamento oral de libertaÇço modificada de pelo menos um princÍpio ativo sob a forma multimicrocapsular | |
DK1526839T3 (da) | Orale farmaceutiske former for flydende lægemidler med forbedret biotilgængelighed | |
FR2358162A1 (fr) | Compositions pharmaceutiques basiques renfermant un preservateur | |
HUP0105173A2 (hu) | Adagolási módszer és készítmény sürgősségi fogamzásgátlásra | |
DE602004020494D1 (de) | Analgetische verbindungen, deren synthese und pharmazeutische zusammensetzungen, die diese enthalten | |
ATE298324T1 (de) | Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel | |
HK1119596A1 (en) | Use of yrazolopyrimidinone derivative in the preparation of agent for the prevention and treatment of liver diseases | |
MA29453B1 (fr) | Associations synergiques de medicaments anti-inflammatoires non steroidiens avec des ligands d'alpha-2-delta | |
MA29333B1 (fr) | Preparations pharmaceutiques d'aerosol pour aerosols-doseurs pressurises contenant un agent sequestrant | |
ATE410152T1 (de) | Therapeutisches system mit amoxicillin und clavulansäure | |
WO2003061557A3 (fr) | Compositions pharmaceutiques a base de levothyroxine, methodes de fabrication et d'administration associees | |
SE0203817D0 (sv) | New composition | |
WO2020044114A3 (fr) | Composition pharmaceutique de méthotrexate | |
AR054710A1 (es) | Formulacion de proteinas mutadas de staphylococcal enterotoxina c1 (sec1) y metodo para su formulacion | |
MA31744B1 (fr) | Compositions pharmaceutiques lyophilisees | |
DE60008392D1 (de) | Nicht-hygroskopische salze aktiver inhaltsstoffe, die therapeutische und/oder ernährungsphysiologische eigenschaften haben und oral verabreichbare zusammensetzungen, die diese enthalten |